Most triptans were developed and introduced in the 1990s. Further studies have not shown much promise regarding the development of new triptans with better duration of action, efficacy and safety profile. Therefore, it is unlikely that further variations will be developed and new anti-migraine drugs are likely to have another mechanism of action.